Amicus Therapeutics Inc. | Ownership
Companies that own Amicus Therapeutics Inc.
Perceptive Advisors LLC
20,024,424
10.59%
0
6.15%
06/30/2018
The Vanguard Group, Inc.
15,869,900
8.39%
581,475
0.01%
06/30/2018
BlackRock Fund Advisors
14,097,519
7.45%
674,304
0.01%
06/30/2018
Fidelity Management & Research Co.
11,347,901
6%
-248,300
0.02%
06/30/2018
Redmile Group LLC
10,511,732
5.56%
-226,926
4.38%
06/30/2018
Jennison Associates LLC
10,094,767
5.34%
-240,700
0.12%
06/30/2018
venBio Select Advisor LLC
9,369,150
4.95%
-136,297
4.3%
06/30/2018
Henderson Global Investors Ltd.
8,178,387
4.32%
-367,952
0.05%
06/30/2018
Wellington Management Co. LLP
8,096,364
4.28%
-147,969
0.02%
06/30/2018
SSgA Funds Management, Inc.
7,962,456
4.21%
-587,121
0.01%
06/30/2018
| Address |
1 Cedar Brook Drive
Cranbury New Jersey 08512
United States
|
|
Employees
|
- |
| Website |
http://www.amicusrx.com |
| Updated |
07/08/2019 |
| Amicus Therapeutics, Inc. is a biotechnology company, which is engaged in the discovery, development and commercialization of novel treatments for patients living with rare and orphan diseases. Its product include migalastat HCl, which is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy for fabry disease. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |
